October 2, 2019

 

VIA EDGAR

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

  Re: Titan Pharmaceuticals, Inc.

Registration Statement on Form S-1, as amended (File No. 333-233722)

 

 

Ladies and Gentlemen:

 

As the underwriter of the proposed offering of Titan Pharmaceuticals, Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time, on October 3, 2019, or as soon thereafter as is practicable. 

   

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 

 

  Very truly yours,
   
  Maxim Group LLC
   
  By:  /s/ Clifford A. Teller               
    Name: Clifford A. Teller
Title: Head of Investment Banking, Executive
Managing Director